Reimbursement Approval from Health Insurers in Saudi Arabia

NZX/ASX Announcement

12 February 2024
TruScreen Secures Reimbursement Approval from Health Insurers in Saudi Arabia
Highlights
• TruScreen screening procedure is approved for reimbursement by most private health
insurance companies in Saudi Arabia,
• The approval reduces the costs for women choosing TruScreen over conventional Pap
Smear in private hospitals.
TruScreen Group Limited (NZX/ASX:TRU) is pleased to announce its distributor, Bettalife, in Saudi Arabia
has successfully obtained reimbursement approval from most health insurance companies in the
country. With reimbursement in place, women who are insured and opt for TruScreen over the
conventional Pap Smear will receive TruScreen at a cheaper price point, making the advanced screening
technology more accessible and cost-effective.


The subsidised costs for TruScreen usage will drive adoption within the private healthcare sector. Private
health insurance is growing in Saudi Arabia, and is obligated for non-Saudis.


Dr. Beata Edling, the CEO of TruScreen, expressed enthusiasm about the private insurer reimbursement
approvals, stating, "This reflects the growing acceptance of TruScreen technology world-wide and
demonstrates our dedication to providing accessible and reliable cervical cancer screening. This
approval will benefit women in Saudi Arabia and contribute to the continued success and expansion of
TruScreen in the region."

“TruScreen's achievement of private insurers’ reimbursement approval in Saudi Arabia is a testament to
the company's commitment to advancing women's healthcare globally, and achieving our ultimate goal,
‘A world without cervical cancer’.”

This announcement has been approved by the Board.
ENDS
For more information, visit

www.truscreen.com or contact:
Beata Edling
Chief Executive Officer
beataedling
@truscreen.com
Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and
manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via
measurements of the low level of optical and electrical stimuli.
TruScreen’s cervical screening technology enables cervical screening, negating sampling and
processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly,
specialised personnel and supporting laboratory infrastructure.
The TruScreen device, TruScreen Ultra
®
, is registered as a primary screening device for cervical
cancer screening.
The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the
TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and
COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the
Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a
manufacturing facility in China for devices marketed and sold in China.
TruScreen technology has been recognised in CSCCP’s (Chinese Society for Colposcopy and
Cervical Pathology) China Cervical Cancer Screening Management Guideline.
TruScreen has been recognised in a China Blue Paper “Cervical Cancer Three Stage Standardized
Prevent and Treatment” published on 28 April 2023.
In financial year 2023 alone, over 140000* examinations have been performed
with TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam,
Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen’s vision is “A world without the cervical
cancer”
©
.
To learn more, please visit: www.truscreen.com/.
*Based on Single Use Sensor sales.

Glossary:
Pap smear (the Papanicolaou smear) test involves gathering a sample of cells from the cervix, with
a special brush. The sample is placed on a glass slide or in a bottle containing a solution to
preserve the cells. Then it is sent to a laboratory for a pathologist to examine under a
microscope. https://www.cancer.net/navigating-cancer-care/diagnosing-cancer/tests-and-
procedures/pap-test
LBC (the liquid-based cytology) test, transfers a thin layer of cells, collected with a brush from the
cervix, onto a slide after removing blood or mucus from the sample. The sample is preserved so
other tests can be done at the same time, such as the human papillomavirus (HPV)
test https://www.cancer.net/cancer-types/cervical-cancer/diagnosis

HPV (human papilloma virus) test is done on a sample of cells removed from the cervix, the same
sample used for the Pap test or LBC. This sample is tested for the strains of HPV most commonly
linked to cervical cancer. HPV testing may be done by itself or combined with a Pap test and/or
LBC. This test may also be done on a sample of cells which a person can collect on their own.
https://www.cancer.net/cancer-types/cervical-cancer/screening-and-prevention

Sensitivity and specificity mathematically describe the accuracy of a test which reports the
presence or absence of a condition. If individuals who have the condition are considered "positive"
and those who don't are considered "negative", then sensitivity is a measure of how well a test can
identify true positives and specificity is a measure of how well a test can identify true negatives:
• Sensitivity (true positive rate) is the probability of a positive test result, conditioned on
the individual truly being positive.
• Specificity (true negative rate) is the probability of a negative test result, conditioned on
the individual truly being negative (Sensitivity and specificity – Wikipedia).
For more information about the cervical cancer and cervical cancer screening in New Zealand and
Australia, please see useful links:
New Zealand: National Cervical Screening Programme | National Screening Unit (nsu.govt.nz)
Australia: Cervical cancer | Causes, Symptoms & Treatments | Cancer Council